CClinicalTrials.gg
TerminatedNCT01893814Updated Sep 22, 2016

Benefit and Tolerability of a Probiotic Product in Infants With Abdominal Discomfort

A Phase 2 interventional study of Probiotics and Control in Abdominal Discomfort, sponsored by Probi AB. Terminated at 1 site in Germany. Open to participants aged 2 Weeks to 12 Weeks. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Probi AB · Phase 2, Interventional, and Treatment

Why this study was terminated
Poor recruitment
Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
2 Weeks to 12 Weeks
Sex
All
01

Study summary

To demonstrate benefit and tolerability of a probiotic product in infants with abdominal discomfort.

02

Conditions studied

  • Abdominal Discomfort
03

In context

Lead sponsor

Probi AB is the lead sponsor of 21 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Weeks to 12 Weeks
Sexes eligible
All

Inclusion criteria

  • Male or female singleton
  • ≥ 2 weeks and ≤ 12 weeks of age
  • Exclusively breastfed at screening
  • Abdominal discomfort (infant colic) in the week prior to enrollment, according to the statement of the parent(s) and/or guardian(s)
  • Episodes of fussy crying that lasted at least 3 hours a day for at least 3 days in the 7 days prior to enrollment, according to the statement of the parent(s) and/or guardian(s)
  • Voluntary, written informed consent of the parent(s) and/or guardian(s) to participate in the study
  • Born at full term (37-42 after last menstruation period)
  • Birth weight: 2500 - 4500 g
  • Weight-for-age ≥ 3th and ≤ 97th percentile according to WHO growth tables / charts
  • Apparently healthy at birth (Apgar ≥ 8) and at screening visit
  • No major complications during pregnancy or at birth
  • Mother 19-45 years of age at childbirth
  • Ability of parent(s) and/or guardian(s) to attend visits, interviews and willingness to fill out questionnaires

Exclusion criteria

Exclusion Criteria:

  • Intolerance to investigational product/its ingredients
  • Severe medical condition or illness, congenital abnormality
  • Gastrointestinal disorders (e.g. reflux esophagitis)
  • Intake of probiotics and/or antibiotics in the week preceding recruitment and during the study
  • Formula feeding at screening/randomisation
  • Allergy or atopic disease (family history)
  • Participation in another study
  • Mother's health condition that may interfere with her ability to take care of her infant
  • Mother affected by hepatitis B, HIV or Guillain-Barré Syndrome
  • Use of antibiotics by the mother in the week
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    Probiotics

    Dietary Supplement: Probiotics

  • Placebo comparator
    Control

    Dietary Supplement: Control

Interventions

  • Dietary supplementProbiotics
  • Dietary supplementControl
06

What researchers measure

Primary outcomes

  1. Reduction of abdominal discomfort as assessed by comparison of crying time

    Time frame: 28 days

07

Study locations

1 site
  • Charité Virchow Hospital
    Berlin, 13353, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01893814
Lead sponsor
Probi AB
Responsible party
Sponsor
First posted
Jul 9, 2013
Start date
Apr 2013
Primary completion
Jan 2014
Last update
Sep 22, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion